Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Locations now list multiple states (Arizona, California, Florida, Georgia, Kansas, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Texas, Washington), expanding trial site access. Revision: v3.3.3 appears after v3.3.2.
    Difference
    1%
    Check dated 2025-12-23T08:28:54.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A new revision tag 'Revision: v3.3.2' is shown and the prior 'Revision: v3.3.1' tag is removed. This is a minor administrative update that does not change study information or user-facing functionality.
    Difference
    0.0%
    Check dated 2025-12-01T17:11:18.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The Publications section now states that these publications are automatically filled in from PubMed and shows Revision: v3.3.1, replacing the prior note tied to v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:35:51.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The general government funding/operating status notice was removed from the page. Study details and links remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-17T06:53:34.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The REVEAL trial was terminated after Phase 1 results, and Phase 2 will not proceed. The termination was not due to safety concerns.
    Difference
    0.4%
    Check dated 2025-11-03T01:20:27.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    } , but actually there is a deletions list including 'Cutaneous neuroendocrine carcinoma' which appears to remove a term, and an addition that updates to v3.2.0 along with a government funding notice about operating status. The core page content has been updated (new version number) and a critical notice about government funding and operating status has been added, which affects users' understanding of site reliability. The deletion of a medical term may adjust content relevance but does not outweigh the new status and update information. Overall, the page now communicates current operating status and a new software version, while removing a specific medical term. If a more concise interpretation is needed: the page adds a prominent operating-status notice and a new version, and removes a previously listed medical term.
    Difference
    3%
    Check dated 2025-10-05T10:31:09.000Z thumbnail image

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.